臨床腫瘍学: 症例報告

Use of COVID-19 Convalescent Plasma as Prophylaxis in a Patient with New Onset All

William R Hartman, Aaron S Hess and Joseph Connor

Patients with hematologic cancers are vulnerable to infection with Severe Acute Respiratory Disease-Coronavirus-2 (SARS-CoV-2), the virus responsible for COVID-19, given their immunodeficiency due to their pathology and their chemotherapy. We present a case report of a patient with severe immunodeficiency secondary to his newly diagnosed Acute Lymphoblastic Leukemia who incidentally was found to be infected with the novel coronavirus. In an attempt to avoid serious manifestations of COVID-19, this patient was prophylactically administered COVID-19 Convalescent Plasma, an emerging treatment for COVID-19 infection. This patient was asymptomatic from his COVID-19 infection but was a high risk of developing manifestations as he was requiring immediate and intense chemotherapy. Throughout his hospital course, including his several chemotherapy treatments, this patient remained infected with SARS-CoV-2, but did not develop disease.